Each MAT med has its own documentation standard.
Buprenorphine, methadone, and naltrexone are not interchangeable in the note. A general scribe treats them as one drug class.
Solutions · MAT & Addiction Medicine
MAT notes that hold up in a regulatory review.
Buprenorphine, methadone, naltrexone. UDS in the assessment. Cohort tags on the panel.
What generic scribes miss.
Toxicology results need to be in the note.
UDS results, timing, and clinical interpretation belong in the assessment, not in a separate lab order.
Addiction medicine runs on longitudinal history.
Relapse, med changes, crisis episodes. What happened six weeks ago shapes today.
Built for this specialty.
MAT templates under standard DEA registration
Buprenorphine initiation, maintenance, taper, and crisis.
Toxicology-aware timeline
UDS results, medication-assisted levels, and treatment response across visits.
Cohort tagging for MAT patients
Tag the active MAT panel. Filter by medication, stage, or risk level. See who hasn't checked in this week.
From a clinician using Nextvisit
The MAT template was accurate on day one. That doesn't happen with general scribes, you spend six weeks training them on terminology they never fully get.
Recommended plan
Provider+, $199/month
Unlimited notes. Start free, no card.
Used by
- Buprenorphine-waivered prescribers
- Methadone clinic NPs & physicians
- Addiction medicine specialists
- Dual-diagnosis outpatient programs
- Integrated BH + MAT practices
See it on your workflow
Twenty minutes, one mock visit. You leave with a note in your template.
We run a mock session, draft the note, and show the claim. No slides.
Live in 2 weeks or less
BAA signed by default